SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lilja Hans)
 

Sökning: WFRF:(Lilja Hans) > (2005-2009) > Test sensitivity in...

  • Auvinen, Anssi (författare)

Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands.

  • Artikel/kapitelEngelska2009

Förlag, utgivningsår, omfång ...

  • 2009

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/104469
  • https://gup.ub.gu.se/publication/104469URI
  • https://doi.org/10.1158/1055-9965.EPI-09-0146DOI
  • https://lup.lub.lu.se/record/1461749URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Test sensitivity pertains to the ability of a test to identify subjects with the target disorder. In cancer screening, test sensitivity can be estimated using interval cancer incidence as an indicator of false-negative result. A randomized trial provides the optimal approach for estimating test sensitivity, as the control arm provides the expected rates. We estimated the sensitivity of the prostate-specific antigen test using incidence method, i.e., based on incidence of interval cancer among subjects with negative screening results, compared with that in the control arm. Data from three centers in the European randomized screening trial were used to estimate interval cancer incidence (I(I)) among 39,389 men with negative screening tests. This was compared with incidence among the 79,525 men in the control arm of the trial (I(c)) to estimate test sensitivity (S = 1 - I(I) / I(C)). Confidence intervals were calculated using simulations, assuming that the number of cases follows a Poisson distribution. The estimated test sensitivity following the first screen was 0.87 (0.83-0.92) in Finland, 0.87 (0.62-1.00) in Sweden, and 0.93 (95% confidence interval, 0.90-0.96) in the Netherlands. There was some indication of a higher test sensitivity for aggressive cancers (0.85-0.98 for non-organ-confined cases or Gleason 8-10) and for the second screening round (approximately 0.85-0.95). Test sensitivity varied to some extent between the three centers in the European trial, probably reflecting variation in screening protocols, but was acceptable in the first screening round, and may be better for aggressive cancers and in the second screening round.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Raitanen, Jani (författare)
  • Moss, Sue (författare)
  • de Koning, Harry J (författare)
  • Hugosson, Jonas,1955Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xhugjo (författare)
  • Tammela, Teuvo (författare)
  • Roobol, Monique (författare)
  • Lilja, HansLund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups(Swepub:lu)klke-hli (författare)
  • Hakama, Matti (författare)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology18:7, s. 2000-51538-7755

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy